Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B

Alice M. Jenh, Paul A. Pham

Research output: Contribution to journalReview articlepeer-review

Abstract

Tenofovir is a nucleotide analog reverse transcriptase inhibitor approved recently by the US FDA for the treatment of chronic hepatitis B (CHB) in adult patients based on the results of two double-blind randomized trials demonstrating superiority of tenofovir compared with adefovir. Tenofovir is available orally as tenofovir disoproxil fumarate (ester pro-drug of tenofovir) and inhibits replication of both hepatitis B virus and HIV-1. Owing to its potent antiviral activity, favorable safety profile, and higher barrier to the development of resistance, tenofovir has replaced adefovir as a first-line oral monotherapy option in the treatment of CHB in the 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines. Additionally, tenofovir monotherapy or in combination with nucleoside analogs are options for patients who have developed resistance to other CHB therapies including lamivudine and adefovir.

Original languageEnglish (US)
Pages (from-to)1079-1092
Number of pages14
JournalExpert Review of Anti-Infective Therapy
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2010

Keywords

  • chronic hepatitis B
  • nucleotide analog reverse transcriptase inhibitor
  • tenofovir disoproxil fumarate

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B'. Together they form a unique fingerprint.

Cite this